Effect of colestimide on the concentrations of polychlorinated dibenzo-p-dioxins, polychlorinated dizenzofurans, and polychlorinated biphenyls in blood of Yusho patients.
Oral colestimide was reported to lower the concentration of PCDDs, PCDFs, and PCB in the blood of humans. A pilot study showed that the arithmetic mean total TEQ concentrations of PCDDs, PCDFs, and PCBs in the blood of subjects after the trial decreased approximately 20 % compared to pre-trial levels, suggesting that colestimide could decrease human dioxin levels. We designed the current clinical trial study based on this information. In this study, we examined whether colestimide could reduce the individual congener concentrations of PCDDs, PCDFs, and PCBs in the blood of Yusho patients.



Out of the 36 Yusho patients who participated in the clinical trial, 26 patients self-administered colestimide 3 g/day orally for 6 months. The concentrations of PCDDs, PCDFs and PCBs in the blood of 26 Yusho patients before the trial were compared with those after the trial.



The arithmetic mean total TEQ concentrations of PCDDs, PCDFs, non-ortho PCBs, and mono-ortho PCBs in the blood of the 26 Yusho patients before and after the clinical trial were 42-303 (mean: 130, median: 120) and 43-283 (mean: 132, median: 118) pg TEQ/g lipid, respectively. The sums of the concentrations of 58 PCB congeners measured in the blood of Yusho patients before and after the trial were 321-2643 (mean: 957, median: 872) and 286-2007 (mean: 975, median: 806) ng/g lipid, respectively, indicating that the concentrations of PCDDs, PCDFs, and PCBs after the trial were almost the same as those before the trial. Among congeners of PCDDs, PCDFs, dioxin-like PCBs, and non-dioxin-like PCBs, most congeners of these compounds did not show a statistically significant decrease after the trial.



Colestimide may not be beneficial in reducing the high blood levels of dioxin-like compounds in Yusho patients.
Kitakyushu Life Science Center, Public Interest Incorporated Foundation, Nakabarushinmachi 1-4, Tobata-ku, Kitakyushu-shi, Fukuoka, 804-0003, Japan. todaka@klsc.or.jp.
Takashi
T
Todaka
Kitakyushu Life Science Center, Public Interest Incorporated Foundation, Nakabarushinmachi 1-4, Tobata-ku, Kitakyushu-shi, Fukuoka, 804-0003, Japan.
Akinori
A
Honda
Kitakyushu Life Science Center, Public Interest Incorporated Foundation, Nakabarushinmachi 1-4, Tobata-ku, Kitakyushu-shi, Fukuoka, 804-0003, Japan.
Masami
M
Imaji
Fukuoka Institute of Health and Environmental Sciences, 39, Mukaizano, Dazaifu-shi, Fukuoka, 818-0135, Japan.
Yoshiko
Y
Takao
Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan.
Chikage
C
Mitoma
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan.
Masutaka
M
Furue
D000368:Aged; D000369:Aged, 80 and over; D000072338:Dibenzofurans, Polychlorinated / Q000097:blood*; D004785:Environmental Pollutants / Q000097:blood*; D004811:Epichlorohydrin / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D011078:Polychlorinated Biphenyls / Q000097:blood*; D000072317:Polychlorinated Dibenzodioxins / Q000097:blood*; D011164:Porphyrias / Q000097:blood*; D012117:Resins, Synthetic / Q000494:pharmacology*
D000072338:Dibenzofurans, Polychlorinated; D004785:Environmental Pollutants; D007093:Imidazoles; D000072317:Polychlorinated Dibenzodioxins; D012117:Resins, Synthetic; C417427:colestimide; D004811:Epichlorohydrin; D011078:Polychlorinated Biphenyls
Blood concentration; Colestimide; PCBs; PCDDs; PCDFs; Yusho